Tesamorelin and Sermorelin – key differences

Tesamorelin and sermorelin are peptides that stimulate natural growth hormone (GH) production, but they are used for slightly different purposes and have varying levels of clinical validation [1–4]. Tesamorelin is generally considered to be more potent and better studied for visceral fat reduction and improving metabolic health, whereas sermorelin is more commonly associated with general growth hormone support, healthy aging, regeneration, and hormonal optimisation [1–4].

Tesamorelin has been approved by the FDA for the reduction of excess visceral fat in individuals with HIV-related lipodystrophy, while sermorelin was originally used for the diagnosis and treatment of growth hormone deficiency in children, and later began to be used off-label in wellness therapies and hormone optimisation in adults [1,5].

Both peptides act via a similar hormonal pathway. They bind to growth hormone-releasing hormone (GHRH) receptors in the anterior pituitary gland, stimulating the body to secrete its own GH [2,6]. Increased GH levels then enhance the production of insulin-like growth factor-1 (IGF-1), which influences fat metabolism, tissue repair, maintenance of muscle mass, regeneration, and energy regulation [2,6].

However, there are significant structural differences between these peptides. Tesamorelin is a stabilised synthetic version of human GHRH consisting of 44 amino acids and includes a specific modification with trans-3-hexenoic acid, which improves stability and prolongs activity in the body [1,7]. Sermorelin, on the other hand, contains only the first 29 amino acids of natural GHRH and is considered a classic GHRH analogue [6].

Tesamorelin has significantly stronger clinical evidence regarding the reduction of visceral fat, abdominal fat and fatty liver disease. In large Phase III trials, Falutz et al. (2010) demonstrated that tesamorelin reduced visceral fat by approximately 15.4% over 26 weeks, whilst improving triglyceride levels and cholesterol ratios without a significant deterioration in glycaemic control [8]. Long-term studies have shown that these effects could be maintained for up to 52 weeks of continuous therapy [9].

Further research by Stanley et al. (2014) showed that tesamorelin significantly reduced both visceral fat and hepatic fat in people with HIV and excessive abdominal fat accumulation [10]. Subsequent studies on HIV-associated NAFLD demonstrated a relative reduction in hepatic fat of approximately 37% after 12 months of therapy [11].

Research into sermorelin focuses more on restoring natural GH production and supporting healthy ageing than on directly impacting visceral fat. Corpas et al. (1992) demonstrated that sermorelin increased GH and IGF-1 levels in older individuals towards values more comparable to those observed in younger individuals [3]. Khorram et al. (1997), on the other hand, found that long-term sermorelin therapy improved lean body mass, skin thickness, insulin sensitivity, libido, and general well-being in older women and men [4]. Vittone et al. (1997) also showed that nocturnal sermorelin injections increased natural nocturnal GH secretion without inducing excessively high hormone levels [12].

Another significant difference is the intensity of hormonal action. Tesamorelin usually causes a stronger increase in IGF-1 and more pronounced changes in visceral fat and metabolic markers [8–11]. Sermorelin, on the other hand, is considered milder and more physiological, meaning it may more gently mimic natural GH signalling originating from the hypothalamus. For this reason, sermorelin is often chosen for healthy ageing or hormone optimisation programmes focused on long-term body support, sleep quality, recovery, and gradual support of natural GH production, rather than aggressive fat reduction or metabolic therapy [3,4,12].

Both peptides are generally considered safer than direct recombinant human growth hormone (HGH) therapy, as they stimulate the body to produce its own GH instead of administering the hormone externally. In studies of tesamorelin, the most commonly reported adverse effects include:

• Injection site reactions
• mild water retention and swelling
• joint pain (arthralgia)
• sporadic glucose control problems [8,9]

The adverse effects of sermorelin are usually mild and can include:

• reddening of the skin
• Headaches
• nausea
• dizziness
• irritation at the injection site [4,6]

As both peptides increase GH and IGF-1 activity, monitoring metabolic and hormonal parameters remains important, particularly in individuals at risk of diabetes, with endocrine disorders, or a history of cancer.

In practice, tesamorelin is usually the better-documented option when the goal is evidence-based visceral fat reduction, improvement of fatty liver disease, and support for metabolic health, particularly in individuals with central obesity or HIV-associated lipodystrophy [8–11]. Sermorelin is more commonly used in the context of general hormonal optimisation, healthy ageing, regeneration, sleep quality, and gradual support of natural GH production [3,4,12].

Generally speaking, the better choice depends on the primary goal of therapy. Tesamorelin is stronger in terms of its impact on metabolism and body composition, whereas sermorelin is often perceived as a milder option for long-term GH support and wellness-oriented hormone optimisation.

From the perspective of the research peptides market, peptides such as tesamorelin and sermorelin are also available from suppliers such as Semax Polska for laboratory and scientific research purposes only.

Disclaimer

This content is for educational and informational purposes only and does not constitute medical, diagnostic or therapeutic advice. Tesamorelin and sermorelin affect the growth hormone and IGF-1 axis and should only be used under the supervision of a qualified specialist with appropriate laboratory monitoring. Individual responses, risks and legal status may vary depending on medical history and country. Research-use-only peptides offered by suppliers such as Semax Polska are intended solely for laboratory and scientific research.

References

1. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. (2018). Tesamorelin. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases.
2. Pombo, C. M., Zalvide, J., Gaylinn, B. D., et al. (2000). Growth hormone-releasing hormone stimulates mitogen-activated protein kinase. Endocrinology, 141(6), 2113–2119. https://doi.org/10.1210/endo.141.6.7513
3. Corpas, E., Harman, S. M., Piñeyro, M. A., Roberson, R., & Blackman, M. R. (1992). Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. The Journal of Clinical Endocrinology & Metabolism, 75(2), 530–535. https://doi.org/10.1210/jcem.75.2.1379256
4. Khorram, O., Laughlin, G. A., & Yen, S. S. C. (1997). Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. The Journal of Clinical Endocrinology & Metabolism, 82(5), 1472–1479. https://doi.org/10.1210/jcem.82.5.3943
5. Prakash, A., & Goa, K. L. (1999). Sermorelin: A review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs, 12(2), 139–157. https://doi.org/10.2165/00063030-199912020-00007
6. Bowers, C. Y. (1998). Growth hormone-releasing peptide (GHRP). Cellular and Molecular Life Sciences, 54(12), 1316–1329. https://doi.org/10.1007/s000180050257
7. PubChem. (2025). Tesamorelin Compound Summary. National Centre for Biotechnology Information, National Library of Medicine.
8. Falutz, J., Mamputu, J. C., Potvin, D., Moyle, G., Soulban, G., Loughrey, H., Marsolais, C., Turner, R., & Grinspoon, S. (2010). Effects of tesamorelin (TH9507), a growth hormone-releasing factor analogue, in human immunodeficiency virus-infected patients with excess abdominal fat: A pooled analysis of two multicentre, double-blind placebo-controlled phase 3 trials with safety extension data. The Journal of Clinical Endocrinology & Metabolism, 95(9), 4291–4304. https://doi.org/10.1210/jc.2010-0490
9. Falutz, J., Allas, S., Mamputu, J. C., et al. (2008). Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS(14), 1719–1728. https://doi.org/10.1097/QAD.0b013e32830a5058
10. Stanley, T. L., Feldpausch, M. N., Oh, J., et al. (2014). Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: A randomised clinical trial. JAMA, 312(4), 380–389. https://doi.org/10.1001/jama.2014.8334
11. Stanley, T. L., Fourman, L. T., Feldpausch, M. N., et al. (2019). Effect of tesamorelin on non-alcoholic fatty liver disease in HIV-positive individuals: A randomised, double-blind, multicentre study. The Lancet HIV, 6(12), e821–e830. https://doi.org/10.1016/S2352-3018(19)30338-8
12. Vittone, J., Blackman, M. R., Busby-Whitehead, J., et al. (1997). Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men. Metabolism, 46(1), 89–96. https://doi.org/10.1016/S0026-0495(97)90174-8